NCT07100873RecruitingPhase 1
A Phase 1 Study of ADI-001 in Rheumatoid Arthritis
A Phase 1 Study of ADI-001 Anti-CD20 CAR-engineered Allogeneic Gamma-Delta (γδ) T Cells in Adults With Treatment-refractory Rheumatoid Arthritis
Source: ClinicalTrials.gov · Last updated 8 Dec 2025
Brief summary (registry, in English)
ADI-001-106 is a phase 1 study of ADI-001 with a randomized, single-blind, parallel group design to compare two different LD regimens in subjects with treatment-refractory RA. The study will consist of different periods including screening, LD, treatment, and follow-up
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 25 (estimated)
- First submitted
- 28 Jul 2025
- Start date
- 10 Oct 2025
- Primary completion date
- 30 Mar 2027
- Lead sponsor
- Adicet Therapeutics
- Diseases
- Rheumatoid arthritis
- NCT number
- NCT07100873
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 25
- From 10 Oct 2025 to the primary completion date, 30 Mar 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- History of a clinically significant infection (including sepsis, pneumonia, bacteremia, fungal, viral and opportunistic infections) within 4 weeks prior to first dose of study drug which in the opinion of the Investigator may compromise the safety of the subject in the study.
Other illness
- Presence of severe liver disease, Child-Pugh class B or C.
- Autoimmune disease requiring prednisone higher than 0.5 mg/kg/day (or corticosteroid equivalent).
Other
- Subjects unwilling to participate in an extended safety monitoring period (LTFU protocol)
Who the study is looking for
- ≥ 18 years of age.
- Fulfills the 2010 ACR-EULAR RA classification criteria
- Agreement not to take traditional medicines and medications not prescribed by a doctor
- Adequate hematological, liver, cardiac and pulmonary function
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Adicet Clinical Trials Coordinator of this site? Confirm its status | Shanghai | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.